IXC invex therapeutics ltd

Ann: Invex Granted Key European Patent for Exenatide, page-50

  1. 428 Posts.
    lightbulb Created with Sketch. 60
    Or it could just be time and the market. Had you put your money elsewhere over the past 12 months you would have made a lot more than parking it here. OPT's share price is struggling for the same reason. Investors know that they can come back to this stock in a few months and pay a comparable price. FYI, I very confidently sold my entire IXC allocation after the Phase 2 result announcement knowing that there'd be this dip between P2 and P3 trials. The instos will jump back in soon - very confident of that. And especially now that the EU patent has been granted.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
9.0¢
Change
0.000(0.00%)
Mkt cap ! $6.763M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 5 9.2¢
 

Sellers (Offers)

Price($) Vol. No.
9.7¢ 9000 1
View Market Depth
Last trade - 16.21pm 14/07/2025 (20 minute delay) ?
IXC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.